{'fraction_non_alphanumeric': 0.04229934924078091, 'fraction_numerical': 0.020607375271149676, 'mean_word_length': 4.80503144654088, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Beta-thalassaemia and the prevalence of HCV viraemia.

Twenty-four serum samples from multitransfused patients with beta-thalassaemia major and fourteen positive control samples, (eight haemodialysis patients and six sporadic cases of HCV infection) were selected as anti-HCV-positives by a second-generation ELISA, a confirmatory test (Abbott), and an immunoblot assay (INNO-LIA HCV AbIII, Omicron Medical). Subsequently, by means of the nested polymerase chain reaction technique (PCR), using the set of PT1-4 primers, the RNA of the virus was detected in a total of 29 samples: 22 out of 24 patients with beta-thalassaemia and 7 out of 14 from the control group were positive for the RNA of the virus. The findings show that there is a statistically significant prevalence [chi2 = 6.344, P < or = 0.02] of HCV viraemia in the population of beta-thalassaemia major in Greece, as compared with the positive control group.